Citations

Showing 10 of 108152 citations.

A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases
Hook, Carl C., Call, Timothy G. , Shah, Meera , Go, Ronald S.

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 3302-3302

10.1182/blood.v126.23.3302.3302 Get It

Background: Large granular lymphocyte (LGL) leukemia is a lymphoproliferative disorder of mature cytotoxic T- or Natural Killer (NK)-cells. T-cell LGL (T-LGL) leukemia is characterized by accumulation of cytotoxic T-cells in blood and infiltration of the bone marrow, liver, or spleen. T-LGL leukemia may manifest as asymptomatic persistent lymphocytosis or present with a myriad of autoimmune diseases including autoimmune cytopenias. Population-based studies have not been reported in LGL leukemia. Here, we present clinical characteristics, natural history, and risk factors for poor survival in patients with T-LGL leukemia using the Surveillance, Epidemiology, and End Results Program (SEER) and the National Cancer Data Base (NCDB), the two largest national cancer registries in the US. Methods: We queried the SEER and NCDB databases using ICD-O histology code 9831 corresponding to LGL leukemia. The query was further refined to include patients with T-LGL leukemia only. Incidence rates (case/1,000,000) were calculated using 2000-2011 data from SEER and age-adjusted to the US 2000 standard population. Patient level data were obtained from the NCDB and used to describe patient characteristics such as demographics, year of diagnosis, treatment, and survival. Results: The incidence of LGL leukemia was 0.2 cases/1,000,000 individuals. The incidence did not change significantly over the period of time studied. The incidences according to racial groups were (mean, 95%CI): White 0.2 (0.18-0.24), Black 0.14 (0.07-0.24), American Indian/Alaska native 0.24 (0.03-0.8), and Asian/Pacific Islander 0.15 (0.07-0.25). The incidences among Blacks, American Indians/Alaska Natives, or Asian/Pacific Islanders were not significantly different compared to Whites. Patient-level data was available for 978 patients with T-LGL leukemia. The median age at diagnosis was 66.5 years (range, 19-90) with a male to female ratio of 1.05. Females were diagnosed at a younger age compared to males (65 vs. 68 years, p<0.05). Forty-five percent of the patients with T-LGL leukemia required some form of systemic treatment at the time of diagnosis. The vital status of 760 (77.7%) patients was known at the time of last follow up with a median follow up of 32 months (range, 0-152). At the time of last follow up, 75.5% were alive with the median overall survival (OS) of 108.4 months (Figure 1). Multivariate analysis that included age at diagnosis, sex, race, year of diagnosis, and Charlson-Deyo co-morbidity score, showed that older age (>60 years) and higher co-morbidity score (≥2) were independent predictors of poorer survival (Table 1). Conclusions: We present the first population-based study of patients with LGL leukemia, an extremely rare disease. The incidence has remained stable over the last decade and does not vary significantly among races. Most patients with T-LGL leukemia do not require treatment and the overall prognosis is relatively good. Table 1. Multivariable analysis showing predictors of mortality in patients with T-LGL leukemia Parameter Hazard Ratio Lower CI Upper CI P -Value Age <60 vs ≥ 60 years 2.73 1.90 4.04 <.0001 Male vs Female 0.82 0.61 1.09 0.19 White vs Other 0.99 0.97 1.00 0.23 Charlson-Deyo score <2 vs ≥2 2.03 1.29 3.06 0.003 Year of Diagnosis (2001-2006 vs. 2007-2012) 1.11 0.76 1.69 0.58 Figure 1. Overall survival in patients with T-LGL leukemia Figure 1. Overall survival in patients with T-LGL leukemia Disclosures No relevant conflicts of interest to declare.
N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
Merlini, Giampaolo , Lacy, Martha Q. , Baudi, Francis K., Kumar, Shaji , Hayman, Suzanne R. , Lust, John A., Kapoor, Prashant , Zeldenrust, Steven R., Hwa, Yi L. , Kyle, Robert A. , Merlini, Giampaolo , Milani, Paolo , Gertz, Morie A. , Palladini, Giovanni , Leung, Nelson , Dingli, David , Lin, Yi , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 3292-3292

10.1182/blood.v126.23.3292.3292 Get It

Abstract Background: Both MM specific and patient specific parameters place patients at risk for death. Patient frailty has been delineated primarily by age and ECOG performance score (PS) and secondarily with creatinine, eGFR, and the International Staging System (ISS), which reflect both renal function and disease burden. In an attempt to improve upon these commonly used measures, a frailty score for elderly patients that combines functional status [Activity of Daily Living (ADL) and Instrumental Activity of Daily living scores], comorbidities [Charlson comorbidity index (CCI)] and age has been developed by the IMWG. Incorporation of these tools into a busy clinical practice is challenging due to time constraints. Therefore, the identification of frail patients with an easily applicable, rapid and objective tool remains a challenge and an unmet need. A reliable, non-invasively assessable, biochemical marker of frailty would be an ideal tool to identify patients at higher risk of death. It was our goal to determine the role of NT-proBNP, a well-established cardiovascular risk biomarker, as a marker of frailty in patients with MM and in predicting overall survival (OS). Methods: Patients were elegible for this retrospective study if they were seen at the Mayo Clinic, Rochester, MN within 30 days of their myeloma diagnosis during the interval between 1/1/2007 and 12/31/2011. As part of the Mayo Clinic registration, all patients complete forms containing their past medical history, symptoms, and ADLs. Data from that first visit was abstracted and used to calculate a CCI. We excluded all patients with a concomitant diagnosis of light-chain AL amyloidosis. NT-proBNP concentration was measured in frozen sera collected within 30 days of diagnosis. NT-proBNP assay was run on the E170 Modular analyzer (Roche Diagnostics, Penzberg, Germany). We evaluated the prognostic role of NT-proBNP and these indices on OS using the Kaplan-Meier method. Results: Among the 351 consecutive patients satisfying entry criteria, median age was 65 years (range 22-95), 33% were ≥70 years, and 56% were male. Twenty-eight percent were ISS stage III, 13% had a creatinine ≥2 mg/dL, 19% had PS ≥2, and 11% had ADL score ≥2, and 30% CCI ≥2. The median value of NT-proBNP was 109 ng/L (interquartile range: 30-375 ng/L). NT-proBNP concentrations differed in the three ISS stages (median: 122 ng/L stage I, 190 ng/L stage II and 1822 ng/L stage III, P<0.0001). Median OS was 5.6 years. The best cutoff of NT-proBNP predicting OS at one year was 301 ng/L (sensitivity: 57.88%, specificity: 74.29%; AUC=0.668) and distinguished two groups with different OS (median not reached vs. 35 months, P<0.0001). Variables predictive for OS are shown in the Table and included PS, age, CCI, ISS, NT-proBNP. On multivariate analysis, ISS and NT-proBNP were independent of each other as long as age, PS and/or CCI were excluded from the model. NT-proBNP withstood these clinical variables better than did ISS (data not shown). We built two different models (table). In model 1, NT-proBNP >301 ng/L was an independent predictor of survival while age ≥70 and PS ≥2 and CCI were not significant. However, if we considered ISS stage instead of NT-proBNP in the same model, ISS stage was not significant. Conclusions: In this unselected cohort of patients with newly diagnosed multiple myeloma, NT-proBNP was a useful predictor of survival independent of age and PS. The threshold of 301 ng/L is remarkably similar to the well-established cutoff for heart failure of 300 ng/L. NT-proBNP outperformed the CCI and the ISS as risk factors. NT-proBNP is a widely available biomarker that could be added to the panel of laboratory tests of newly diagnosed MM patients and serve as a simple means of determining patient frailty in a busy clinical practice. Table. Results of univariate and multivariate analysis of various prognostic factors (NS, not significant; NI, not included). Univariate Multivariate Multivariate RR (95% CI) P Model 1 P Model 2 P PS ≥2 3.4 (2.4-4.8) <0.0001 2.5 (1.7-3.6) <0.0001 2.8 (1.9-4.0) <0.0001 Age ≥70 2.7 (1.9-3.6) <0.0001 2.1 (1.5-2.9) <0.0001 1.9 (1.3-2.7) 0.0003 CCI >=2 1.9 (1.4-2.6) <0.0001 NS NS 1.5 (1.0-2.0) 0.03 ISS stage 1.1 (1.1-1.8) 0.0004 NI NI NS NS NT-proBNP >301 ng/L 2.3 (1.7-3.2) <0.0001 1.6 (1.1-2.2) 0.007 NI NI Disclosures Merlini: Janssen-Cilag: Honoraria; Prothena: Honoraria; Millennium-Takeda: Honoraria; Pfizer: Honoraria. Kumar:Janssen: Research Funding; Celgene: Research Funding; Sanofi: Research Funding; Millenium/Takeda: Research Funding; AbbVie: Research Funding; Onyx: Research Funding; Celgene, Millenium, Sanofi, Skyline, BMS, Onyx, Noxxon,: Other: Consultant, no compensation,; Skyline, Noxxon: Honoraria.
Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors
Xochelli, Aliki , Kavakiotis, Ioannis , Kienle, Dirk, Davis, Zadie , Yan, Xiao‐Jie , Boudjogra, Myriam, Chatzouli, Maria, Pedersen, Lone Bredo , Facco, Monica , Moreno, Denis, Chu, Charles C. , Catherwood, Mark , Montillo, Marco , Geisler, Christian H., Pospı́šilová, Šárka , Lefranc, Marie‐Paule , Oscier, David , Jelinek, Diane F., Belessi, Chrysoula, Davi, Frédéric , Darzentas, Nikos , Sutton, Lesley‐Ann, Hadzidimitriou, Anastasia , Agathangelidis, Andreas , Shanafelt, Tait D. , Plevová, Karla , Veronese, Silvio , Giudicelli, Véronique , Panagiotidis, Panagiotis T. , Vlahavas, Ioannis P. , Anagnostopoulos, Αchilles , Maglaveras, Nicos , Trentin, Livio , Langerak, Anton W. , Chiorazzi, Nicholas , Stilgenbauer, Stephan , Ghia, Paolo , Rosenquist, Richard , Chouvarda, Ioanna , Σταματόπουλος, Κώστας

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 1969-1969

10.1182/blood.v124.21.1969.1969 Get It

Abstract The human IGHV4-34 gene encodes antibodies which are intrinsically autoreactive when the VH domain is unmutated. Therefore, B cells expressing IGHV4-34 B-cell receptor immunoglobulins (BcR IG) are normally under close scrutiny in order to avoid unwanted autoreactivity, especially against DNA. The IGHV4-34 gene is frequently utilized in chronic lymphocytic leukemia (CLL), where, typically, it shows a high load of somatic hypermutation (SHM). We have previously reported distinctive SHM patterns amongst IGHV4-34 CLL, especially for subsets with stereotyped BcR IG. However, although a large number of cases (~2000) was previously studied, since even the largest subsets account for only ~3% of CLL, meaningful conclusions could not be reached for smaller subsets. Here we revisit this issue in a series of 16,528 CLL cases and focus on IGHV4-34 expressing subsets: #4 (IGHV4-34/IGHD5-18/IGHJ6 | 156 cases, 0.9%); #11 (IGHV4-34/IGHD3-10/IGHJ4 | 16 cases, 0.1%); #16 (IGHV4-34/IGHD2-15/IGHJ6 | 41 cases, 0.25%); #29 (IGHV4-34/IGHD: unassignable/IGHJ3 | 39 cases, 0.24%); and #201 (IGHV4-34/IGHD: unassignable/IGHJ3 | 43 cases 0.26%). Focusing on codons 27-104 within the VH domain (from CDR1-IMGT to FR3-IMGT), we calculated the sequence distance between subsets and the corresponding IGHV4-34 germline sequence based on a pairwise qualitative and quantitative comparison of the respective amino acid composition. The minimum distance calculated, and hence the greatest identity, was observed between subsets #4 and #16, both concerning IgG-switched cases (IgG-CLL), which is notable given the overall rarity of IgG-CLL. In contrast, the maximum distance, implying the least identity, was between subsets #16 and #201, the latter concerning IgM/D-CLL. Extreme variations between subsets were noted in codons spanning the entire VH domain. This result is consistent with our finding of a subset-biased distribution of mutations over the VH domain. More specifically, while subsets #11, #16, #29 and #201 had a lower frequency of mutations within VH CDR1 compared to VH CDR2, the exact opposite was seen in subset #4, with 40% of mutations in VH CDR1 versus 27% in VH CDR2. In addition, subsets #4, #11, #16 and #29 had a similar distribution of mutations in VH FR2 and VH FR3, in contrast to subset #201 that showed a preference for VH FR3 over VH FR2. Consequently, we noted that certain positions were targeted in a subset-specific manner e.g. codon 28 in VH CDR1 was heavily targeted in subsets #4 (68.6%) and #16 (87.8%), with most cases carrying an acidic amino acid (AA) introduced by SHM, glycine to glutamic acid, G>E: 51.3% for subset #4 and 78% for subset #16. The high prevalence of acidic AA introduced by SHM in these subsets is notable considering the electropositive nature of their VH CDR3 (especially of subset #4), strongly recalling edited anti-DNA antibodies. Interestingly, the G>E change was identified at a much lower frequency in other IGHV4-34 subsets: 18.75% for subset #11; 2.6% for subset #29; 7% for subset #201, all of which carried electronegative VH CDR3. Further, we noted that certain positions were heavily targeted in all subsets e.g. 56-86% targeting for SHM at codon 92 in VH FR3 where serine is encoded by the agc triplet, the ”hottest of hotspots”. This result could be viewed as sequence- rather than subset-dependent and linked to the molecular features of this codon, which is supported by the low targeting of codon 93 (0-6%), also encoding serine by the tct triplet. Other positions were targeted in all subsets but at vastly different frequencies e.g. codon 64 was targeted in 37.8% in subset #4 rising to 100% in subset #29. Finally, positions heavily targeted by SHM in certain subsets were unmutated in other subsets e.g. codon 36 in VH CDR1 remained unmutated in subset #16, in contrast 76.9% of subset #29 were mutated at this position resulting in an AA change. In conclusion, we document different spectra of SHM and AA changes between stereotyped IGHV4-34 CLL subsets. The finding of subset-biased, recurrent AA changes at certain codons indicates that the respective progenitor cells may have responded in a specific manner to the selecting antigen(s), despite expressing the same IGHV gene, indicating a functional purpose for these modifications. This is exemplified by the molecular characteristics of the recurrent AA changes in subset #4, thereby offering interesting pathogenetic hints. Disclosures No relevant conflicts of interest to declare.
Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma
Thompson, Carrie A. , Allmer, Cristine, Yost, Kathleen J. , Macon, William R. , Ansell, Stephen M. , Inwards, David J. , Maurer, Matthew J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 205-205

10.1182/blood.v124.21.205.205 Get It

Abstract Purpose: The purpose of this study was to examine whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma, controlling for clinical variables and histological subtype. Patients and Methods: Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. Eligibility criteria included age ≥18 years; exclusion criteria included HIV-positive, non-US residency, and inability to participate in an interview conducted in the English language. All pathology was reviewed by a lymphoma hematopathologist. For purposes of this analysis, we considered “aggressive lymphoma” to include the histological subtypes diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) grade III, mantle cell lymphoma, T-cell lymphoma excluding mycosis fungoides and cutaneous types, and other (Burkitt lymphoma, high grade B-cell lymphoma NOS, grey zone, etc). Baseline QOL was measured at time of registry enrollment with the Functional Assessment of Cancer Treatment-General scale (FACT-G), which measures 4 QOL domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self Assessment (LASA) for measuring overall QOL; and a LASA measuring spiritual WB. Patients who did not complete ≥80% of FACT-G QOL questions were excluded. Clinical data were abstracted and patients were systematically followed for event-free and overall survival (EFS, OS). QOL scores were transformed to a 0-100 scale for modeling. Generalized additive models were used to account for timing of QOL assessment in relation to treatment and diagnosis; residuals from these models were then used to assess association between QOL measures and outcome via univariate and multivariable (adjusted for IPI and subtype) Cox proportional hazards models. Results: From September 2002 to December 2009, 701 patients with aggressive lymphoma who completed baseline QOL questionnaires were enrolled and eligible for this analysis. ; Subtype was 60% DLBCL, 14% mantle cell, 11% FL grade III, 13% T-cell, and 1% other subtypes. The median age was 62 years (range 18-92), and 58% were male. At a median follow-up of 71 months (range 6-128), 316 patients (45%) had an event and 228 patients (33%) died. Patient-reported QOL was prior to therapy in 330 patients (47%) and after initiation of therapy in 371 (53%). The median overall FACT-G total score was 83 (IQR 70-93), and the median scores on the functional WB, physical WB, emotional WB, and social/family WB were 18 (13-23), 22 (17-26), 18 (16-21), and 25 (22-27), respectively. 42 patients (6%) reported a clinically deficient QOL score on the FACT-G (score ≤50 on 0-100 scale). When comparing QOL scores between those who were on active therapy versus those who were not yet treated, physical WB (p<0.0001) functional WB (p=0.00014), and total FACT-G (p=0.0013) were lower in those on active treatment. All QOL measures but emotional WB were significantly associated with OS (all p<0.04), and all but LASA spiritual WB remained significant after adjusting for IPI and NHL subtype. Associations were stronger for OS than EFS. For OS, the strongest associations were with total FACT-G (adjusted HR=0.86, 95% CI: 0.79-0.94, p=0.00062) and functional WB (adjusted HR=0.88, 95% CI: 0.83-0.93, p<0.0001). The one-question QOL LASA was also associated with OS (adjusted HR=0.92, 95% CI: 0.87-0.97, p=0.0041). The strongest association with EFS was with functional WB (adjusted HR=0.92, 95% CI: 0.88-0.97, p=0.0015). Patients with a clinically deficient QOL (baseline overall QOL ≤50) had a median OS of 59 months compared to 121 months for patients with baseline QOL >50, p=0.0002, figure 1. In a sensitivity analysis, raw QOL was modeled for OS and EFS in the subset of patients with QOL assessed prior to treatment; hazard ratios were consistent with the adjusted QOL HR in all patients. Conclusions: In this large sample of patients with aggressive lymphoma, baseline QOL is predictive of OS and EFS, even after adjustment for known factors related to survival (IPI and histological subtype). This provides evidence that patient-reported outcomes are as important as other more objective previously confirmed IPI measures. QOL should be assessed at diagnosis as a prognostic factor in patients with aggressive lymphoma. Figure 1 Association of QOL with overall survival. Figure 1. Association of QOL with overall survival. Disclosures No relevant conflicts of interest to declare.
DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription
Jung, Sungwon , Seungchan, Kim, Gale, Molly, Carpten, John D. , Salhia, Bodour , Fonseca, Rafaël

Mayo Clinic

Blood | October 10, 2019 | Volume: 120 | Issue: 21 | Pages: 1285-1285

10.1182/blood.v120.21.1285.1285 Get It

Abstract Abstract 1285 Introduction: Recent studies have now demonstrated that both genic and global hypomethylation characterizes the multiple myeloma (MM) epigenome. We previously conducted a study to measure changes in DNA methylation at approximately 1500 CpG (GoldenGate Methylation BeadArray, Illumina) loci in 193 MM samples used in the Multiple Myeloma Research Consortium Genomics Initiative. The purpose of this study was to determine the extent to which DNA methylation changes in MM correlate to changes at the gene expression level. Methods: To evaluate this correlation we performed three independent analyses. In the first approach we analyzed matching gene expression and DNA methylation data using a Pearson correlation to assess the linear relationship between the datasets. In the second approach methylation and gene expression data from 193 matching samples were quantile-normalized and standardized across genes and samples. Methylation data was then discretized into three groups (methylated, unchanged, unmethylated) according to the mean and standard deviation of the values for each probe on the array. We then computed a t-test to compare the gene expression differences for each gene represented on the methylation array between samples in the methylated and unmethylated groups. We also performed a class enrichment analysis to assess DNA methylation/gene expression correlations that might be associated with hyperdiploidy or molecular subtype. In the third approach we performed RT-PCR and methylation pyrosequencing to validate results in a subset of samples used for the analysis and in an independent cohort comprised of 50 MM samples. Results: By Pearson correlation, only 31 (2.1%) CpG loci (corresponding to 24 unique genes) had a gene expression probe with a statistically significant correlation. Using the discretization approach, we identified 382 loci (25.3%, 309 unique genes) with methylation-expression correlations. Although we identified more correlations by discretizing the data, methylated and unmethylated samples were represented by an average of only 30 and 27 samples per group. We identified correlations where the directionality of methylation and expression values were either in the opposite (negative) or same direction (positive). Among the genes identified, the tumor suppressor genes CDKN2A and DLC1 interestingly demonstrated a positive correlation (methylated and expressed) and the IGF1R and IL17RB genes were negatively correlated (unmethylated and expressed). A class enrichment analysis revealed that samples with DLC1, CDKN2A, IGF1R or IL17RB methylation were associated with hyperdiploid MM. Conversely, samples that were unmethylation for these genes were generally non-hyperdiploid. These findings were validated by RT-PCR and methylation pyrosequencing. Conclusion: Overall, our findings demonstrated, albeit in a limited number of genes, that DNA methylation changes are weakly associated to gene expression. These data suggest that CpG methylation may have other functional consequences such as predisposing the genome to global gene transcriptional changes or chromosomal instability. While future studies are needed to determine the exact role of DNA methylation, we identified a number of genes regulated by an epigenetic mechanism with important clinical and biological implications to MM and warrant further study. Disclosures: No relevant conflicts of interest to declare.
Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial
Leong, Traci , Kyle, Robert A. , Greipp, Philip R., Billadeau, Daniel D. , Ness, Brian Van, Bone, Nancy D., Oken, Martin M., Kay, Neil E.

Mayo Clinic

Blood | October 10, 2019 | Volume: 90 | Issue: 1 | Pages: 340-345

10.1182/blood.v90.1.340 Get It

AbstractRecent analyses of circulating blood B cells in myeloma have generated controversy concerning the exact levels of these cells and whether they may represent circulating clonal tumor B cells. Previous reports suggested that CD19+ B cells are markedly increased in myeloma patients and that this population shares clonotypic rearrangements with the malignant plasma cell. We studied the numbers of CD19+ B cells by flow cytometry in previously untreated newly diagnosed myeloma patients in Eastern Cooperative Oncology Group (ECOG) phase III trial E9486. There were 628 patients who were eligible for the clinical protocol E9486, but of these 521 were also entered on the companion laboratory study (E9487) and had CD19 data. In comparison with normal controls, the myeloma patients exhibited a marked heterogeneity in the number of circulating CD19+ B cells as detected by flow cytometry. Approximately 20% of patients had significantly increased levels of circulating CD19+ B cells. However, the total CD19+ blood population from myeloma was not significantly different from the median of age-matched, normal controls. Analysis of CD19+ blood cells in relationship to circulating clonal cells was done in 13 myeloma patients using a clonotypic, quantitative allele-specific oligonucleotide-polymerase chain reaction (PCR) assay. No correlation was found between the numbers of CD19+ B cells (range, 5% to 51%) and PCR estimates of the number of clonal cells in the peripheral blood (range, .009% to 3.6%). Low CD19+ B-cell level (&lt;125 μL) was associated with clinical stage III (P = .033). A significant relationship exists between higher levels (≥125/μL) of CD19 cells and longer overall survival (P &lt; .0001). In addition, high CD19 levels also predicted a clinical response and longer event-free survival. There was a strong inverse association between the level of CD19 values at diagnosis and infections within the first 2 months of diagnosis. Importantly, the number of deaths related to infections was significantly greater in the low versus high CD19 group (P &lt; .0202). Also, CD19 is an independent prognostic factor in addition to plasma cell labeling indices, β2 -microglobulin, hemoglobin, and plasmablastic morphology. Patients with infections were more likely to have low levels of CD19+ cells. In summary, higher CD19+ cell levels are a favorable prognostic sign with no apparent relationship to circulating tumor cells. In addition, this analysis strongly suggests that low peripheral blood levels of CD19+ cells are an adverse prognostic sign in myeloma. The CD19+ cell levels in myeloma patients is an important parameter in the overall assessment of these patients.
Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)
Mahindra, Anuj, Saad, Ayman , Zhang, Mei‐Jie , Zhong, Xiaobo , Krishnan, Amrita , Pasquini, Marcelo C. , Saad, Ayman , Dispenzieri, Angela , Lonial, Sagar , Hari, Parameswaran

Mayo Clinic

Blood | October 10, 2019 | Volume: 120 | Issue: 21 | Pages: 4217-4217

10.1182/blood.v120.21.4217.4217 Get It

Abstract Abstract 4217 Background: AHCT improves survival (OS) in newly diagnosed MM patients (pts) in large randomized trials. These trials have limited eligibility to younger, healthier pts. Selection of older pts and those with co-morbid illness for AHCT is problematic. HCT-CI, originally developed as predictor of post-allogeneic transplant outcomes, maybe valuable in stratifying risk of transplant related mortality (TRM) risk and OS in the AHCT setting. We investigated the relative impact of HCT CI along with other patient and MM related variables on outcomes after AHCT in a large cohort of transplant recipients. Methods: Outcomes of 1156 MM pts receiving AHCT after high dose Melphalan (MEL) between 2007 and 2010 reported to the CIBMTR (Center for International Blood and Marrow Transplant Research) were analyzed. HCTCI scores and individual comorbidities were prospectively reported at time of AHCT. Median follow up of survivors was 26 month. The impact of HCTCI and other potential prognostic factors including Karnofsky performance status (KPS) on OS were studied in multivariate Cox regression models. Results: HCTCI score was 0, 1, 2, 3, >3 in 42%, 18%, 13%, 13% and 14% respectively. Most common co-morbidities included pulmonary, diabetes, obesity, psychiatric, cardiac, renal and prior solid tumor. Using consolidated HCTCI scores, patients were stratified initially into 3 risk groups – HCTCI 0 (42%) vs. HCTCI 1–2 (32%) vs. HCTCI >2 (26%). Males and Caucasians were more likely to have greater HCTCI score. Higher HCTCI was associated with lower KPS <90 (33% in HCTCI 0 cohort vs. 50% in HCTCI >2). HCTCI score >2 was associated with MEL dose reduction to 140 mg/m2 (22% vs. 10% in score 0 cohort). Cytogenetic risk and MM related factors were not correlated with HCTCI. TRM at 12 month was 2%, 2%, and 3% for 3 risk groups. With extremely few TRM events, multivariate analysis did not suggest an impact of HCTCI. OS was 95%, 92%, 92% at 1 year and 87%, 81%, 80% at 2 year, respectively. OS was inferior for HCTCI >2 cohort (RR of death 1.48, p=0.02) and HCTCI cohort 1–2 (RR 1.37, p=0.04) compared with HCTCI 0 cohort. There was no significant difference in OS between HCTCI >2 vs. HCTCI 1–2 (p=0.64). Therefore the latter 2 groups were combined as the HCTCI >0 cohort [N=667] and compared with HCTCI=0 [N=489] in multivariate models. HCTCI >0 predicted inferior OS (RR of death= 1.41, p=0.01). Other significant predictors of inferior survival were KPS <90 (RR of death 1.61, p<0.01), IgA subtype (RR 1.64, p<0.01), >1 pretransplant regimen (RR 1.47, p<0.01), resistant MM at AHCT (RR 1.78, p<0.01). Major cause of death in both groups was progressive MM. Conclusion: In clinical practice, higher HCTCI score was associated with MEL dose reduction. Mortality after AHCT is predominantly related to MM progression/relapse with low incidence of TRM. Higher HCTCI scores were independently associated with inferior OS. KPS remains an important tool for risk stratification. Disclosures: No relevant conflicts of interest to declare.
Ikaros Degradation Efficiency Correlates with Response of Multiple Myeloma (MM) Cells to IMiD Therapy and Is Blocked By Proteasome Inhibitors
Shi, Chang‐Xin, Zhu, Yuan Xiao , Jedlowski, Patrick , Bruins, Laura A., Kortuem, Martin, Stewart, A. Keith

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 2247-2247

10.1182/blood.v124.21.2247.2247 Get It

Abstract Background: It is now well established that the immune modulator (IMiD) drugs thalidomide (Thal), lenalidomide (Len) and pomalidomide (Pom) bind a specific pocket in the protein, cereblon (CRBN) that is required for MM cytotoxicity after IMiD treatment. Recently, we reported 46 CRBN binding proteins which were altered by Len, two of which were the transcription factors Ikaros (IKZF1) and Aiolis (IKZF3), important regulators of B and T cell development. Others had previously reported the same finding and went further by demonstrating that following binding of IMiD drugs, CRBN accumulates and accentuates the ubiquitination and subsequent proteasomal degradation of these two binding proteins. The resulting degradation and depletion of IKZF proteins has the simultaneous effect of downregulating IRF4 and MYC leading to MM cell death while simultaneously enhancing transcription of interleukin 2 and activating the immune compartment. Methods: To further explore this phenomenon and its relationship to drug sensitivity we first created two stable MM cell lines (H929IKZF1Luc, 8226IKZF1Luc) expressing an IKZF1-luciferase (luc) fusion gene and tested for sensitivity to Len alone and in combination with dexamethasone (Dex), bortezomib (Bor) or the histone deacetylase inhibitor SAHA. Next, we constructed an adenoviral vector expressing IKZF1-luc and used this to transfect 16 MM cell lines, confirmed expression and tested sensitivity to Len by MTT (Figure 1). Results: We first examined the stable cell lines and measured luc expression after exposure to all three IMiD drugs. With all IMiD drugs luc dramatically decreased in sensitive H929 cells. IKZF1 depletion was both time and dose dependent. Using this surrogate marker cell line assay, luc is most efficiently degraded by Pom which is twice as potent as Len, but a thousand times more potent than Thal (Concentration of drug required to reduce luc expression by 50%, Pom: 4.9nM, Len: 10.2 nM, and Thal: 4,795 nM). We then tested all 16 cell lines with Len 2uM for 5 hours and show a strong correlation of IKZF-luc depletion with sensitivity. Figure 1: Luc levels 5 hours after Len treatment at 2uM. We divided the cell lines into three groups: 1) Len resistant: 8226, KMS12PE, My5, SKMM2, JJN3, FR4, H112; 2) Len intermediate response: EJM, OPM2, U266, KMS18; 3) Len sensitive: H929, MM1.S, MM1.R, KMS11, XG1; Figure 1:. Luc levels 5 hours after Len treatment at 2uM. We divided the cell lines into three groups: 1) Len resistant: 8226, KMS12PE, My5, SKMM2, JJN3, FR4, H112; 2) Len intermediate response: EJM, OPM2, U266, KMS18; 3) Len sensitive: H929, MM1.S, MM1.R, KMS11, XG1; We next performed western blots on 9 MM cell lines and demonstrate that IKZF1 levels were lowest in 3 of 5 resistant MM cell lines and normal in all 4 sensitive lines studied. The cell line (FR4) with the lowest levels of IKZF1 harbors a damaging mutation of IZKF1 as well as a translocation which upregulates IRF4, an IKZF target. Of the remaining two resistant lines one has low levels of Cereblon. In one line the mechanism of IMiD resistance could not be established. Finally, we were curious about the dichotomy of the IMiD biology which seemingly has an absolute requirement for a functional proteasome for successful IMiD cytotoxicity which is at variance with clinical reports of synergy between the IMiDs and the proteasome inhibitors (PIs) Bor and carfilzomib (Car). To explore this, we treated the 8226IKZF1Luc cell line with Len alone or in combination with increasing concentrations of Bor (6 nM) or Car (40nM) and found that both totally blocked IKZF1 fusion protein degradation promoted by Len, beginning as soon as 1 hour at 100nM Bor or after 3 hours at 40nM treatment. Conversely, in low concentration of Bor (<4nM) no IKZF1 degradation blocking was observed in the Luc assay and Bor remained lethal to the MM cells. In that light with lower levels of Bor (<3nM) even varying the sequencing of MM cell exposure to the two drug classes did not block cytotoxicity. Other MM active drug Dex or SAHA, blocking the aggresome, had no significant inhibition for Len-induced IKZF1 fusion protein degradation. Conclusion: These results validate the central role for the CRBN-IKZF-IRF4 axis proteins in IMiD response and show a strong correlation of IZKF1 expression and the ability to degrade IKZF1 with sensitivity. Our data provide interesting and perhaps disconcerting biologic data suggesting that the timing and dosing of clinical use of IMiDs and PI treatment in combination should be carefully evaluated to prevent antagonism of effect but suggest in vitro that a therapeutic window exists at which proteasome inhibitors can be active without blocking IMiD activity. Disclosures Stewart: Sanofi: Consultancy; Array BioPharma: Consultancy; Bristol Myers Squibb: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Takeda Pharmaceuticals International Co.: Research Funding.
UNUSUAL REMISSION AFTER RADIOPHOSPHORUS THERAPY IN A CASE OF "ACUTE PLASMA CELL LEUKEMIA"
Bayrd, Edwin D., Hall, Byron E., Hall, Byron E.

Mayo Clinic

Blood | October 10, 2019 | Volume: 3 | Issue: 9 | Pages: 1019-1024

10.1182/blood.v3.9.1019.1019 Get It

Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders
Cardel, Laynalee K., Ashrani, Aneel A. , Heit, John A. , He, Rong , Hook, C. Christopher , Pardanani, Animesh , Rodriguez, Vilmarie , Nichols, William L., Pruthi, Rajiv K. , Patnaik, Mrinal M. , Botero, Juliana Perez , McBane, Robert D. , Warad, Deepti , Wysokiński, Waldemar E. , Chen, Dong

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 3476-3476

10.1182/blood.v126.23.3476.3476 Get It

Abstract Background Congenital/hereditary qualitative platelet disorders (CQPD) can be classified by platelet count (eg, normal or decreased) and platelet size as well as by functional defect. Based on mean platelet volume (MPV), congenital thrombocytopenias (CT) are classified as macro-thrombocytopenias (eg, Bernard-Soulier syndrome [BSS], MYH-9 [myosin heavy chain 9, non-muscle]-associated thrombocytopenias, gray platelet syndrome [GPS], etc.); microthrombocytopenias (eg, Wiskott-Aldrich syndrome and variants); and those with normal platelet size. CQPDs with normal platelet count include Glanzmann thrombasthenia (GT), dense granule storage pool disorders (DG-SPD) including Hermansky-Pudlak syndrome (HPS), platelet secretion disorders and many others. Diagnosis has relied on platelet counting and sizing, blood smear light microscopy, platelet aggregation (agg) and platelet function analyzer (PFA-100) studies. Platelet transmission electron microscopy (PTEM) and flow cytometry can provide supplementary information and molecular analysis is also evolving. The objective of this study was to determine the roles of platelet transmission electron microscopy (PTEM) and flow cytometry in the diagnosis of CQPD and CT. Methods In this retrospective cohort study, after IRB approval, the electronic medical record system was queried for patients (pt) with a confirmed CQPD or CT seen at Mayo Clinic between 2000 and 2015. A detailed chart review was undertaken. Results 54 pt (64% female) met our study criteria; median age was 32 years (range 1 day to 81 years). 18/54 (33%) pt had macrothrombocytopenia: BSS 4 (7%); MYH-9 10 (19%); gray platelet syndrome 4 (7%). 36/54 (66%) had normal MPV: Glanzmann thrombasthenia 6 (11%); storage pool disorders including DG-SPD 10 (19%) and HPS 2 (3%), mild alpha granule deficiency 3 (6%) and York platelet syndrome 4 (7%); platelet secretion disorders 4 (7%); ANKRD26 mutation 3 (6%); congenital amegakaryocytic thrombocytopenia 1 (2%); GATA-1 mutation 1 (2%); RUNX-1 mutation 1 (2%); and Jacobsen syndrome 1 (2%). 44 pt (81%) had a positive bleeding history: epistaxis 52%, cutaneous bleeding 57%, gastrointestinal bleeding 21% and menorrhagia 54%; 10 pt (19%) had a negative bleeding history. Results of standard and esoteric platelet testing are summarized in Table 1. Diagnosis in the 10 pt with glycoprotein deficiency (BSS or GT) was established by agg; flow cytometry was confirmatory but not necessary. Of the 23 pt with SPD, 5 had a negative bleeding history; 4 pt had normal agg and PFA-100 and were diagnosed exclusively by PTEM. In this group, the abnormalities on platelet aggregation and PFA were variable and PTEM allowed for a better definition of the specific abnormalities. For MYH-9 patients, PTEM confirmed leukocyte inclusions that had already been identified on light microscopy. PTEM was the only diagnostic modality able to identify the abnormality in York platelet syndrome. In 5/54 (9%) genetic testing was necessary for diagnosis (GATA-1, ANKRD26 and RUNX-1) Conclusion In this cohort, standard platelet assays established the diagnosis in the large majority of CQPD and CT. PTEM was essential for confirmation in DG-SPD, mild alpha granule deficiency and York platelet syndrome and useful in combination with molecular testing to establish a diagnosis in selected cases. Guidance on selection of patients for such specialized testing requires further study. Table 1. Results of standard and esoteric platelet testing for 54 patients with congenital qualitative platelet disorders and/or thrombocytopenia Disorder n (%) Platelet aggregation PFA PTEM Flow cytometry Confirmation by genetics Done Abnormal Done Abnormal Done Abnormal Done Abnormal Glanzmann thrombasthenia 6 (11) 6 6 5 5 1 0 3 3 0 Bernard-Soulier syndrome & variants 4 (7) 4 4 4 4 3 0 4 4 0 MYH-9 related disorders 10 (19) 7 2 8 3 5 5 4 2 5 Dense granule deficiency and HPS 12 (22) 12 8 12 8 12 12 4 0 0 Alpha granule deficiency* 7 (13) 7 4 7 6 7 7 4 4 1 York platelet syndrome 4 (7) 1 0 1 1 4 4 1 1 0 TXA2 or PG synthesis/receptor defect 4 (7) 4 4 4 3 3 0 3 0 0 CATM 1 (2) 0 - 0 - 0 - 0 - 1 ANKRD26 3 (6) 3 3 3 2 3 3 3 3 3 GATA-1 1 (2) 0 - 1 1 1 1 1 1 1 RUNX-1 1 (2) 1 0 1 1 0 - 0 - 1 Jacobsen syndrome 1 (2) 1 0 1 1 1 1 1 0 1 MYH-9: myosin heavy chain 9, non-muscle (MHY-9) associated thrombocytopenia, HPS: Hermansky-Pudlak Syndrome, TXA2: thromboxane A2, PG: prostaglandin CATM: congenital amegakaryocytic thrombocytopenia. * Includes gray platelet syndrome Disclosures Pardanani: Stemline: Research Funding.